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Abstract
Background: The involvement of miRNAs in the regulation of fundamental cellular functions has placed them at
the fore of ongoing investigations into the processes underlying carcinogenesis. MiRNA expression patterns have
been shown to be dysregulated in numerous human malignancies, including breast cancer, suggesting their
probable involvement as novel classes of oncogenes or tumour suppressor genes. The identification of differentially
expressed miRNAs and elucidation of their functional roles may provide insight into the complex and diverse
molecular mechanisms of tumorigenesis. MiR-183 is located on chromosome 7q32 and is part of a miRNA family
which are dysregulated in numerous cancers. The aims of this study were to further examine the expression and
functional role of miR-183 in breast cancer.
Methods: MiR-183 expression was quantitated in primary breast tumours, tumour associated normal tissue and
breast cancer cell lines using RQ-PCR. Gain of function analysis was performed in breast cancer cells using pre-miR-
183 and the effect of miR-183 overexpression on cell viability, proliferation, apoptosis and migration was examined.
Customized Taqman Low Density Arrays (TLDA) were used to identify dysregulated genes in breast cancer cells
transfected with pre-miR-183.
Results: We demonstrate that miR-183 is dysregulated in breast cancer and expression correlates with estrogen
receptor and HER2/neu receptor expression. Induced overexpression of miR-183 inhibited migration of breast
cancer cells. This finding was substantiated by RQ-PCR of mRNA from cells overexpressing miR-183 which showed
dysregulation of several migration and invasion related genes. Specifically, the VIL2-coding protein Ezrin was
confirmed as a target of miR-183 and downregulation of this protein was confirmed with immunocytochemistry.
Conclusions: These findings indicate that miR-183 targets VIL2 and may play a central role in the regulation of
migration and metastasis in breast cancer. Consequently, this miRNA may present an attractive target for
therapeutic intervention.
Background
Breast cancer is a heterogeneous disease and represents
a number of phenotypically diverse tumours [1]. The
complex nature of breast cancer makes progression dif-
ficult to predict and challenging to manage. Up to forty
percent of breast cancer patients still present with regio-
nal or distant disease progression at the time of diagno-
sis [2], and the overall survival rates for these patients
has changed very little in the past decade despite
advances in systemic therapy.
The key to optimising breast cancer management lies
in early detection, effective prognostication and
individualised therapy, all of which demand a compre-
hensive understanding of the complex molecular inter-
actions that underlie breast cancer development and
progression. Gene expression profiling has gone some
way towards unlocking the heterogeneity of breast can-
cer; the advent of such high throughout technologies as
microarray expression profiling facilitated the extensive
investigation of breast cancer related genes [3-5]. Breast
tumors can now be classified into major subtypes on the
basis of gene expression: luminal, HER2/neu overexpres-
sing and basal-like, and further analysis has identified
additional subtypes within the original sub-groups [6].
Multigene prognostic and predictive tests have been
developed, commercialized and have become established
as tools in breast cancer diagnostics [7], however as yet* Correspondence: nicola.miller@nuigalway.ieDepartment of Surgery, National University of Ireland, Galway, Ireland
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there is little knowledge regarding the precise regulation of
these genes and receptors, and the precise manner in
which they drive breast cancer progression and metastasis.
Mi(cro)RNAs represent a fascinating new division of
biomolecules. The analysis of their expression will help
decipher complex patterns in disease states such as
malignancy, and promises to improve classification of
tumors such as breast cancer [8] in addition to uncover-
ing pathogenic pathways and therapeutic avenues.
The aim of this study was to investigate the potential
role of a specific miRNA miR-183 in breast cancer pro-
gression. MiR-183 is a member of a miRNA family com-
prised of three homologous miRNAs (miR-183, miR-182
and miR-96) that are clustered within 2-4 kb at chromo-
some 7q32. MiRNAs from this locus are dysregulated in
diverse cancers including leukaemia, hepatic, colorectal
and breast cancer [9-13]. Furthermore, downregulation
of miR-183 has been shown to be associated with metas-
tasis in lung cancer, and its’ ectopic expression inhibits
the invasiveness of cancer cells [14], suggesting that
miR-183 plays a role in carcinogenesis or the metastatic
cascade, possibly having a tumour suppressor role.
In this study we investigated the expression pattern and
functional role of miR-183 in breast cancer. This was
undertaken by quantitation of miR-183 in breast cancer
specimens in relation to known clinicopathological para-
meters of breast cancer. Functional analysis was then per-
formed by transfection of miR-183 precursors into a
breast cancer cell line with low endogenous miR-183
levels. The effects of transfection were subsequently
assessed on cell viability patterns, cell migration and
alterations in gene and protein expression by real-time
quantitative PCR and immunocytochemistry respectively.
The findings of this study support a role for miR-183
in breast cancer, particularly in the metastatic process,
and identify this miRNA as a novel therapeutic target in
breast cancer.
Methods
Clinical Samples
Breast tumour specimens were obtained from patients
during primary curative resection at Galway University
Hospital, Galway, Ireland. Matched tumour-associated
normal (TAN) breast tissue was also obtained from a
subset of these patients where possible. Following exci-
sion, tissue samples were immediately snap-frozen in
liquid nitrogen and stored at -80°C until RNA extrac-
tion. Prior written and informed consent was obtained
from each patient and the study was approved by the
ethics review board of Galway University Hospital. A
cohort of fresh frozen breast tumor (n = 70) and TAN
(n = 9) specimens was used for analysis of miR-183
expression. Clinical and pathological data relating to the
clinical samples are shown in table 1.
Cell Lines and Culture Conditions
The cell lines used in this study included MDA-MB-231
estrogen, progesterone and HER2/neu receptor negative
(ER-, PR-, HER2/neu-), T47D (ER+, PR+, HER2/neu-),
SKBR-3 (ER-, PR-, HER2/neu+) and ZR-75-1 (ER+,
PR+, HER2/neu+). The media used for each cell line
Table 1 Breast tumor clinicopathological characteristics
Breast Cancer Clinicopathological
Characteristics
Number of
Patients
N = 70
Median Patient Age yrs (IQR) 52 (48-64)
Median Tumor Size mm (IQR) 25 (20-35)
Histologic Subtype
Invasive Ductal 59
Invasive Lobular 6
Colloid/Mucinous 2
Tubular 2
Papillary 1
Intrinsic Subtype
Luminal A (ER/PR+, HER2/neu-) 38
Luminal B (ER/PR+, HER2/neu+) 7
HER2 Overexpressing (ER-, PR-, HER2/neu+) 10
Triple-Negative (ER-,PR-,HER2/neu-) 9
Missing data 6
Grade
1 13
2 17
3 38
Missing data 2
Nodal Status
Node Negative 46
N1 8
N2 11
N3 5
ER Status
-ER Positive 41
-ER Negative 29
PR Status
PR Positive 41
PR Negative 27
Missing data 2
HER2/neu Status
HER2 Positive 18
HER2 Negative 47
Missing data 5
UICC Stage
Stage 1 19
Stage 2a 28
Stage 2b 4
Stage 3a 9
Stage 3b 3
Stage 3c 5
Stage 4 2
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were as follows: MDA-MB-231-Lebowitz L15, T47D and
ZR-75-1-RPMI-1640, SKBR-3-McCoy-5A. Media was
supplemented with 10% FBS and 2 units/mL penicillin
G/100 mg/mL streptomycin sulfate. Cells were main-
tained at 37°C, 5% CO2 with a media change twice
weekly and passage every 7 days. Prior to transfection
experiments, cells were cultured for at least 48 hours in
the appropriate antibiotic-free media supplemented with
10% FBS and 1% L-Glutamine.
Separate miRNA and Large RNA extraction
Large (> 200 nucleotide) and small RNA (< 200 nucleo-
tide) fractions were isolated separately from cultured
cells using the RNeasy Plus Mini Kit and RNeasy MinE-
lute® Cleanup Kit (Qiagen, West Sussex, UK) according
to the Supplementary Protocol: Purification of miRNA
from animal cells. The concentration and purity of RNA
were assessed using a NanoDrop™ 1000 spectrophot-
ometer (Nanodrop Technologies, DE, USA). Large RNA
integrity was assessed using the RNA 6000 Nano Lab-
Chip Series II Assay with the 2100 Bioanalyzer System
(Agilent Technologies, Palo Alto, CA, USA) which gen-
erated the RNA integrity number (RIN) to ensure that
only RNA of good integrity was used in these experi-
ments (RIN range 7.0 - 9.5). Small miRNA enriched
fractions were analysed using the Small RNA Assay on
the Agilent 2100 Bioanalyzer.
Quantitative Reverse Transcription of mature miRNAs
RQ-PCR quantification of miRNA expression was
performed using TaqMan® MicroRNA Assays accord-
ing to the manufacturer’s protocol (Applied Biosys-
tems, Foster City, CA USA). Small RNA (5 ng) was
reverse-transcribed using the MultiScribe™-based
High-Capacity cDNA Archive kit (Applied Biosys-
tems). RT negative controls were included in each
batch of reactions. PCR reactions were carried out in
final volumes of 20μL using an ABI Prism 7900
Sequence Detection System (Applied Biosystems).
Briefly, reactions consisted of 1.33μL cDNA, 1X
TaqMan® Universal PCR Master Mix, 0.2μM TaqMan®
primer-probe mix (Applied Biosystems). Reactions
were initiated with a 10 minute incubation at 95°C
followed by 40 cycles of 95°C for 15 seconds and 60°C
for 60 seconds. MiRNA-16 and let-7a were used as
endogenous controls to standardize miRNA expression
[15]. An interassay control derived from a breast can-
cer cell line (ZR-75-1) was included on each plate. All
reactions were performed in triplicate. The threshold
standard deviation for intra- and inter-assay replicates
was 0.3. Percent PCR amplification efficiencies (E) for
each assay were calculated as E = (10-1/slope - 1) ×
100, using the slope of the semi-log regression plot of
Ct versus log input of cDNA (10-fold dilution series
of five points) A threshold of 10% above or below
100% efficiency was applied.
Quantitative reverse transcription PCR of mRNA
Aliquots of large RNA equivalent to 1μg were reverse
transcribed using SuperScript™ III reverse transcriptase
(200U/μl, Invitrogen, Calsbad, CA, USA) and random
nanomer primers. RQ-PCR reactions were carried out
using TaqMan® Gene Expression Assay Primers and an
ABI Prism 7900 Sequence Detection System (Applied
Biosystems). The transcription levels of MRPL19 and
PPIA were used as endogenous controls [16].
Relative quantification
The relative quantity of miRNA and mRNA expression
was calculated using the comparative Ct (ΔΔCt) method
[17]. The geometric mean of the Ct value of the endo-
genous control genes was used to normalize the data
and the lowest expressed sample was used as a
calibrator.
Precursor microRNA Transfection
Hsa-miR-183 pre-miR miRNA precursor (Ambion cat.
no. AM17100) was obtained from Ambion. Precursor
molecules were transfected into breast cancer cell lines
using siPORT Amine transfection reagent (Ambion) and
the reverse transfection protocol according to manufac-
turer’s instructions. Culture medium was changed after
24 h of transfection. Transfection effects were evaluated
after 72 hrs. Treatment was performed in triplicate.
Cells transfected with the Pre-miR™ miRNA precursor
molecule - negative control (Ambion, cat. no.
AM17110) were used as a control in all transfection/
gain-of-function experiments. The efficiency of overex-
pression of miR-183 was evaluated by RQ-PCR.
Cell proliferation & apoptosis assay
The ApoGlow adenylate nucleotide ratio Assay Kit
(Cambrex Bioscience, Nottingham, UK) was used to dis-
criminate between inhibition of proliferation, induction
of apoptosis and cell lysis by determination of ADP:
ATP ratios, using the luciferin-luciferase biolumines-
cence assay and in accordance with the manufacturer’s
instructions. In brief, cells were transfected with hsa-
pre-miR-183 or pre-miR-negative control as described,
seeded into 96 well plates at a density of 8 × 103 cells
per well and incubated for 72 hours. 100 μL of nucleo-
tide releasing reagent per well was added and the incu-
bation continued for 5 min. Bioluminescence was
measured (reading A) with a Luminoskan Ascent®
microplate luminometer (Thermo Fisher Scientific)
immediately after the addition of 20 μL nucleotide mon-
itoring reagent per well. After 10 min, 20 μL of ADP
converting reagent was added per well and luminescence
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was recorded (reading B). Reading C was obtained 5
min later and ATP: ADP ratios were calculated as A:
(C-B). These experiments were performed in triplicate.
Migration Analysis: In-Vitro Tracking of Cell Migration
For migration assays, cells were used 72 hours after
transfection with pre-miR-183 or nonsense pre-miR in
basal media. Migration of breast cancer epithelial cells
was analysed using Transwell Permeable Supports. A
suspension of transfected cells was inoculated into the
insert and their migration towards FBS enriched media
was quantified. After an18 hour migration incubation,
cells remaining above the membrane were removed, the
membrane insert was then transferred to ice-cold
methanol to fix cells, followed by staining in hematoxy-
lin. Once dry, the membranes were excised from the
insert and mounted on slides for quantification of
migrated cells (five fields of view on each membrane).
Cell counts were done on an Olympus BX60 microscope
using analySIS software. Each experiment was repeated,
at least in triplicate, with results expressed as mean ±
SD.
Taqman Low Density Array (TLDA)
A TLDA was custom designed and ordered from
Applied Biosystems, containing Gene Expression Assays
capable of measuring mRNA for 94 breast cancer
related genes (96 TaqMan® Gene Expression assay pre-
configured in a 384-well format, Part no. 4342261, Lot
No A3400, microfluidic cards; Applied Biosystems, Fos-
ter City, CA 94404). Each TLDA card was customized
with four identical 96 gene sets to facilitate the analysis
of two samples per card with 2 replicates per gene and
per sample). Each set of 96 genes contained two endo-
genous controls, MRPL19 and PPIA (Additional File 1).
The TLDA cards were used in a two-step reverse tran-
scriptase polymerase chain reaction (RT-PCR) process
using the ABI Prism 7900HT Sequence Detection Sys-
tem (Applied Biosystems) with a TaqMan Low-Density
Array Upgrade (Applied Biosystems). Two samples were
run on each TLDA card; RNA extracted from cells that
were hsa-pre-miR-183 transfected and cells that were
pre-miR-negative control transfected. Each cDNA sam-
ple at a concentration of 1000 ng in 50 μl was added to
an equal volume of TaqMan Universal PCR Master Mix
(Applied Biosystems). After gentle mixing, the solution
(100μl) was transferred into a loading port on a TLDA
card (Applied Biosystems). The loaded TLDA plate was
centrifuged and sealed. The Applied Biosystems 7900HT
Real-Time PCR system was used to perform the real-
time reaction. Thermal cycler conditions were as fol-
lows: 2 min at 50°C, 10 min at 94.5°C and 30 s at 97°C,
and 1 min at 59.7°C for 40 cycles. The comparative Ct
method of relative quantification using MRPL19 and
PPIA as endogenous controls was used and relative
quantification between hsa-pre-miR-183 transfected
samples and negative controls was determined according
to the 2−ΔΔCT method.
Protein Analysis - Immunocytochemistry
Breast cancer cell lines were transfected with hsa-pre-
miR-183 or negative control as described and seeded
into chamber slides. After 72 hours the cells were fixed
by incubation in ice-cold methanol and immunocyto-
chemical analysis performed using a Ventana Discovery™
automated staining platform with a mouse monoclonal
antibody targeting VIL2 (Ezrin) (ab4069, Abcam)
Once staining was completed sections were washed in
warm soapy water, dehydrated in serial alcohol immer-
sions and mounted using DPX mounting medium.
Changes in VIL2 expression following transfection of
breast cancer cells were observed in 5 fields of view
using an Olympus BX60 microscope and image analy-
SIS® software.
Statistical Analysis
All RQ-PCR data were transferred to a statistics compu-
ter package (SPSS 14.0 for Windows) for analysis, and
the Kolmogorov-Smirnov normality test was applied.
Data that were not normally distributed required log
transformation to produce an adequate approximation
to a normal distribution prior to parametric analysis
Comparison of miRNA and mRNA levels between dis-
ease groups and transfection conditions was performed
using one way ANOVA and independent T-tests. Corre-
lation analysis used Pearson’s correlation coefficient and
Spearman’s Rho for parametric and nonparametric data
respectively. Univariate analysis and paired T-tests were
used to assess related samples.
Results
MiR-183 expression in breast tumors
The expression of miR-183 was quantitated in 70
breast tumors, 9 of which had matched TAN tissue
available. RQ-PCR of mature miR-183 in these samples
showed no significant difference in expression between
tumor and tumor associated normal tissue (p = 0.35,
paired t-test). Mature miR-183 was expressed in all the
tumor samples and the expression of miR-183 was sig-
nificantly lower in ER positive breast tumors compared
to ER negative tumors with a fold change of 2.97
between the groups, p = 0.01, figure 1a. (mean RQ
87.73 +/-16 vs 260.58+/091 p = 0.01, figure 1a). Con-
versely, miR-183 expression was higher in HER2/neu
receptor positive tumors compared to HER2/neu
receptor negative tumors (mean RQ 329.79+/-150 vs
93.33+/-15 p = 0.012, figure 1c). The expression of
miR-183 is significantly lower in Luminal A tumors
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(mean RQ 76.26+/-13) than the other intrinsic sub-
types, (p = 0.02, ANOVA, figure 1d).
There was a positive correlation between miR-183
expression and tumor size but this did not reach statisti-
cal significance(R = 0.271, p = 0.076). There was no
association of miR-183 with other clinicopathological
parameters, including histological subtype (p = 0.669),
nodal status (p = 0.271), tumor grade (p = 0.326).
MiR-183 expression in breast cancer cell lines
MiRNA was extracted from cell line pellets using the
separate purification protocol. The cell lines were cho-
sen on the basis of their ER, PR and HER2/neu receptor
status and the expression of miR-183 in breast cancer
cell lines mirrored that of the clinical breast tumor sam-
ples, with the lowest expression in T47D cells which are
ER+ve/PR+ve and HER2/neu -ve, and the highest
expression in SKBR-3 cells which are ER-ve/PR-ve and
HER2/neu +ve (figure 2). This finding suggests that
these cell line models of breast cancer subtypes closely
reflect tumor miRNA expression patterns and are a use-
ful in-vitro breast cancer model for functional analysis
of miRNA.
As miR-183 was dysregulated in breast tumors in
association with clinico-pathological parameters ER, PR
and HER2/neu status, we further investigated the role of
miR-183 in breast cancer via gain of function
experiments.
The efficiency of pre-miR-183 transfection was con-
firmed by quantitation of mature miR-183 levels in
miRNA extracted from cells transfected with 20 nm
pre-miR-183 and incubated to 48 and 72 hours. The
highest mature miR-183 levels were seen at 72-hours,
with a mean fold change of more than 6000-times that
of the negative control (figure 3).
MiR-183 represses breast cancer cell migration in-vitro
To further assess the functional role of miR-183 in
breast cancer, the effect of miR-183 overexpression on
cell migration, proliferation and apoptosis were
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Figure 1 MiR-183 Expression in Primary Breast Tumors. Figure 1a: miR-183 expression is significantly higher in ER-negative tumors *p = 0.01,
independent t-test. Figure 1b: miR-183 expression is signifcantly higher in PR-negative tumors *p = 0.03, independent t-test. Figure 1c: miR-183
expression is significantly higher in HER2/neu positive tumors *p = 0.029, independent t-test. Figure 1d: miR-183 expression is significantly lower
in Luminal A tumors compared to all other subtypes p = 0.02, ANOVA.
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evaluated. Migration of pre-miR-183 and pre-miR-nega-
tive control transfected cells in response to FBS
enriched media was tracked using Transwell inserts.
T47D cells transfected with pre-miR-183 showed a sig-
nificant decrease in migration compared to negative
controls. Cell migration was quantified in five fields of
view on each membrane (figure 4).
MiR-183 does not affect proliferation or apoptosis in
breast cancer cells
The ApoGlow™ Adenylate Nucleotide Ratio Assay (Cam-
brex) was used to determine the effect of miR-183 over-
expression on distinct mechanisms underlying
alterations in cell viability. This luciferase-based assay
allows the efficient detection, quantitation and distinc-
tion between apoptosis, necrosis, growth-arrest and cell
proliferation. ATP is a biomarker for the presence of
metabolically active cells, indicative of cell health and
viability and is rapidly consumed if cells are compro-
mised. There was no significant difference in ATP or
ADP levels between miR-183 transfected cells and con-
trols at 72 hours indicating no effect of miR-183 on cell
proliferation, apoptosis or viability.
Changes in gene expression in the presence of increased
miR-183
To further explore the role of miR-183 in breast cancer,
we compared the expression levels of 94 breast cancer
related genes in cells transfected with pre-miR-183 and
pre-miR-negative control. T47D cells were used in this
experiment as they express he lowest levels of endogen-
ous miR-183. Cells were reverse transfected, incubated
for 72 hours and RNA extracted as described. Gene
expression was quantitated by RQ-PCR on a customized
Taqman Low Density Array as described. The fold
change in gene expression in cells overexpressing miR-
183 was calculated relative to the negative control cells
using the comparative Ct method (figure 5a) and the
percentage dysregulation was calculated using the equa-
tion : % downregulation = 100-100 × 2-ΔΔCt. With the
criterion of dysregulation of > 50%, we identified 14
genes that were differentially expressed following trans-
fection of pre-miR-183 compared to negative controls.
Among these genes, there were genes functioning in cell
growth, migration, proliferation and apoptosis, functions
which are inextricably linked to tumor progression
(table 2). The dysregulation of a selection of these genes
was validated by repeating the transfection in triplicate
Figure 2 miR-183 expression in breast cancer cell lines. The
lowest expression of miR-183 is in T47D cells which are ER positive
and HER2/neu receptor negative
Figure 3 premiR-183 transfection efficacy. Mature miR-183 levels
were quantitated in T47D cells following transfection with PremiR-
183 precursor molecules. The fold change represents the level of
mature miRNA in PremiR-183 transfected cells relative to cells
transfected with PremiR-negative control. Fold change was
quantitated using the comparative CT method with miR-16 and let-
7a as endogenous controls and miRNA levels from cells transfected
with premiR-negative control as a calibrator.
Figure 4 Overexpression of miR-183 inhibits migration in T47D
cells. Quantification of migration through 8- m pore inserts by miR-
183 transfected cells as a percentage of that achieved by control
cells. The migratory cell number was significantly less in cells
transfected with pre-miR-183 compared to cells transfected with
pre-miR-negative control (*p = 0.001). In the more aggressive SKBR-
3 and MDA-MB-231 cells the migratory cell number was higher
overall but there was no difference in migratory number between
cells transfected with pre-miR-183 and negative controls.
Experiments were performed in triplicate.
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and quantitating gene expression using conventional
individual Taqman assays. RQ-PCR verified that the
mRNA level of VIl2, MYBL2 and CD68 could be down-
regulated by overexpression of miR-183 (figure 5b).
These genes could be either directly or indirectly
affected by miR-183. To further investigate this, we
employed in silico analysis using three target prediction
programmes (miRBase, TargetScan and PicTar) [18-20].
VIL2 was the only gene that was predicted to have a
binding site for miR-183 in its 3’UTR by all three data-
bases, indicating that VIL2 is likely to be directly
affected by miR-183.
Overexpression of miR-183 alters VIL2 protein expression
in breast cancer cells
To further investigate the nature of VIL2 as a potential
miR-183 target, we evaluated the effect of increased
miR-183 on VIL2 protein expression in T47D and
SKBR3 cells which have distinct hormone and HER2/
neu receptor status profiles. Cells were transfected with
pre-miR-183 or pre-miR negative control, seeded onto
chamber slides which were then fixed and stained with
VIL2 antibody at 72 hours. The proportion and intensity
of staining was evaluated in 5 fields of view using an
Olympus BX60 microscope.
There was positive staining of both pre-miR-183
transfected and negative control T47D cells however
membranous staining of VIL2 appeared stronger in
T47D cells transfected with pre-miR-183 (figure 6a).
In SKBR3 cells, there was reduced cytoplasmic and
membranous staining of VIL2 in cells transfected with
pre-miR-183 compared to negative controls (figure 6b).
This indicates that miR-183 affects VIL2 at both the
mRNA and protein levels.
Discussion
MiRNA expression patterns are altered in breast cancer
as previously described [13,21-24], and expression profil-
ing of miRNA to classify tumors according to clinico-
pathological variables appears to have superior accuracy
to mRNA profiling [8]. This evidence underlines the
role of miRNAs in breast cancer molecular biology and
provides the starting point for exploration of novel
molecular mechanisms.
Quantitation of miR-183 by RQ-PCR in primary breast
tumors revealed that miR-183 expression is significantly
lower in ER and PR positive compared to ER and PR
negative breast tumors, while miR-183 expression was
significantly higher in HER2/neu positive compared to
HER2/neu negative tumors. Luminal A tumors exhibited
the lowest expression of miR-183. This is the first report
of miR-183 dysregulation in association with hormone
and HER2/neu receptor status in clinical breast tumour
samples. Differential expression of miR-183 in breast
cancer cell lines has been demonstrated by Sempere
et al [25] using northern blotting, with decreased
expression in basal-type compared to luminal-type cell
lines. Interestingly, the expression of miR-182 which is
co-ordinately expressed from the same genetic locus as
miR-183 has been shown to be downregulated in ER
positive tumors [13], this supports our finding of miR-
183 dysregulation in association with ER status. The
identification of dysregulated miRNAs in relation to ER
and HER2/neu receptor status in breast cancer is of
great clinical significance as the specific combination of
receptor status has implications for the current classifi-
cation and targeted therapy of breast cancer. The past
decade has seen the development of a molecular taxon-
omy of breast cancer which has been divided into sub-
types based on the expression of specific genes,
including ER and HER2/neu. However, this taxonomy
remains limited because clinical outcome may be vari-
able within each subtype, suggesting the existence of
further divisions that are yet to be characterised; for
example, subgroups have been identified within the
Luminal A and ER positive breast tumours which have
distinct survival and prognostic profiles [26,27]. One
obvious explanation for the lack of homogeneity within
the breast cancer subtypes is the potential dysregulation
of miRNAs between and within subgroups. MiRNAs
represent a new layer of molecular complexity in breast
Figure 5 Dysregulation of mRNAs following induced
overexpression of miR-183. Figure 5a: 14 genes were
differentially expressed in T47D cells transfected with pre-miR-183
compared to negative control. Gene expression was analysed using
TLDA. Figure 5b: RQ-PCR using conventional taqman assays verified
downregulation of a selection of breast cancer associated genes
following transfection of T47D cells with pre-miR-183.
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cancer and miRNA expression profiles are thought to be
more accurate than mRNA at classifying tumours [8].
Their unique ability to requlate gene expression confers
functionality on these molecules, and when dysregulated
in breast cancer they may be responsible for altering the
phenotype of breast tumours. Thus, it is important to
functionally characterise miRNAs, such as miR-183 that
are dysregulated in breast cancer and establish what
effect this dysregulation may have on tumour behaviour.
MiR-183 is located on chromosome 7q32.3 and is part
of a miRNA family comprised of three homologous
miRNAs (miR-183, miR-182 and miR-96) that are co-
ordinately expressed from this locus. MiR-183 family
members have been shown to be upregulated in leukae-
mia, hepatic and colorectal cancer [9-12]. Conversely,
miR-183 has been shown to be downregulated and
inversely associated with metastasis in lung cancer [14].
This evidence indicates that the expression patterns of
miR-183 are tissue specific, and that this miRNA may
have divergent functions depending on the tissue or cell
type. Such context dependence of miRNA function has
previously been reported in the results of biochemical
studies indicating that miRNA repression of mRNA is
dependent on the specific cellular conditions [28].
There has been limited functional analysis of miR-183;
it has been postulated that miR-183 may downregulate
Table 2 Dysregulated genes following overexpression of miR-183
Gene Dysregulation
(%)
Function Putative Target
CAV1 73.12 Tumor suppressor gene candidate. Codes for scaffolding protein No miRBase
No Pictar
NoTargetscan
CD68 70.51 Phagocytosis No miRBase
No Pictar
NoTargetscan
CASP2 67.16 Apoptosis Yes miRBase
No Pictar
Yes Targetscan
BAG3 57.70 Negative regulator of apoptosis, adhesion, migration Yes miRBase
No Pictar
No Targetscan
TPM1 57.53 Actin-binding. Stabilizes cytoskeleton actin filaments No miRBase
No Pictar
Yes Targetscan
BRCA1 57.21 Tumor suppressor, DNA repair No miRBase
No Pictar
No Targetscan
NCOA4 56.08 Ligand-independent coactivator of PPAR-gamma No miRBase
No Pictar
Yes Targetscan
**VIL2 54.51 Linker between plasma membrane and actin cytoskeleton, involved in cell adhesion & migration. Yes miRBase
Yes Pictar
Yes targetscan
SNCG 53.69 Role in neurofilament network integrity. No miRBase
No Pictar
No Targetscan
EPHA2 53.15 Receptor for members of the ephrin-A family No miRBase
No Pictar
Yes Targetscan
MYBL2 52.82 Transcription factor involved in the regulation of cell survival, proliferation, and differentiation No miRBase
No Pictar
No Targetscan
KRAS 52.30 Ras proteins bind GDP/GTP and possess intrinsic GTPase activity No miRBase
No Pictar
No Targetscan
FYN 50.91 Implicated in the control of cell growth No miRBase
No Pictar
No Targetscan
FGFR4 -58.97 Implicated in cell growth, proliferation. No miRBase
No Pictar
No Targetscan
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anti-apoptotic factors including forkhead transcription
factor (FOX) proteins, suggesting a pro-apoptotic func-
tion for this miRNA [9,29], however this was based on
computational analysis and no experimental verification
was provided.
During the course of these experiments, the first func-
tional study of miR-183 in malignancy was reported;
Wang et al [14] identified miR-183 as a potential metas-
tasis inhibitor in lung cancer and demonstrated that
over expression of miR-183 inhibited migration of lung
cancer cells. They reported miR-183 induced dysregula-
tion of expression of genes involved in migration and
invasion, including VIL2. Overexpression of miR-183 in
HeLa cells has also been shown to inhibit migration and
invasion, however this was shown to be mediated
through direct targeting of integrin β1 (ITGB1) [30],
indicating that miR-183 is likely to have a number of
mRNA targets through which it mediates biological
effects in cancer cells.
The functional role of miR-183 in breast cancer was
investigated in these experiments using a gain-of-func-
tion approach. The lowest endogenous expression of
miR-183 was observed in T47D cells, which are ER and
PR positive and HER2/neu negative, making these cells
a suitable in-vitro representation of the Luminal A sub-
type of breast cancer.
The effect of miR-183 modulation on cellular func-
tions which are frequently dysregulated in malignancy
was assessed in T47D cells (ER+, PR+, HER2/neu-),
SKBR3 cells (ER-, PR-, HER2/neu+), and MDA-MB-231
Figure 6 VIL2 expression in breast cancer cells overexpressing miR-183. Figure 6a: stronger membranous staining of VIL2 in cells
transfected with premiR-183 is denoted by the red arrows. Figure 6b: VIL2 staining is weaker in cells transfected with premiR-183.
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(ER-, PR-, HER2/neu-), cells which exhibit distinct hor-
mone and HER2/neu receptor profiles. There was no
effect on apoptosis or proliferation, which refutes the
hypothesis of miR-183 having a pro-apoptotic function.
Induced overexpression of miR-183 resulted in
decreased migration of T47D cells in transwell assays,
but there was no significant change in migration of
SKBR3 or MDA-MB-231 cells (figure 4).
The difference in effect noted between the cell lines is
not completely surprising for a number of reasons;
firstly T47D cells were shown to express the lowest
endogenous levels of miR-183, thus the effect of overex-
pression in these cells would be expected to result in a
more dramatic or measurable phenotypic effect than in
cells where miR-183 is expressed at higher levels endo-
genously. Furthermore, although the three cell lines are
epithelial breast cancer cell lines, they are unrelated and
are phenotypically distinct; differences in cell behaviour
would thus be expected that relate to the previously
mentioned cell-type specific regulatory mechanisms and
actions of miRNA. As miR-183 was shown to be dysre-
gulated in relation to ER and HER2/neu status it is not
unexpected that this miRNA would behave differently
depending on the cell type and environment, particularly
in relation to the expression of these receptors.
The finding that miR-183 reduces migration in breast
cancer cells indicates that this miRNA may play an
important role in the suppression of metastases, as cell
motility and migration are key steps in the metastatic
cascade. These findings are in concordance with the
findings of Wang et al [14] who demonstrated a similar
effect in lung cancer cells. Increasing evidence supports
a role for multiple miRNAs in the regulation of metas-
tases in breast cancer [31-35]. This is hugely significant
as metastasis is the overwhelming cause of mortality in
breast cancer patients, but a complete understanding of
its molecular and cellular determinants remains elusive
[36]. Gene expression profiling studies have provided
gene-sets that are predictive of breast cancer progression
and prognosis [37], however the regulatory networks
that establish such altered gene expression states are
only now coming into focus. It is important that the tar-
gets and regulators of metastasis involved miRNAs are
elucidated to improve our understanding of the specific
roles played by miRNAs in the complex, multistep pro-
cess of primary tumor invasion and metastasis.
To further elucidate the mechanism by which miR-183
regulates metastasis we analysed the expression of 96
breast cancer related genes using a low density array and
identified candidate genes which were dysregulated fol-
lowing transfection of T47D cells with miR-183 (table 2).
T47D cells were chosen for this part of the experiment as
they had shown the greatest phenotypic change in
response to miR-183 modulation. The finding of genes
that are both downregulated and upregulated is in keep-
ing with recent reports that miRNAs are differential
modulators of gene expression and can activate mRNA
translation in addition repression [38]. Functions of the
changed genes were analysed using NetAffx Gene Ontol-
ogy Mining Tool available at the Affymetrix website
http://www.affymetrix.com/ and a number of the genes
were found to have roles in migration and maintenance
of the actin cytoskeleton integrity. These data support
the hypothesis that regulation of metastasis requires
coordinated expression of multiple genes. Computational
prediction algorithms were used to identify which of
these miRNAs may be direct targets of miR-183 via com-
plementary binding at the 3’UTR. All three of the algo-
rithms used (miRBase, PicTar and TargetScan) predicted
VIL2/Ezrin a member of the ezrin/radixin/moesin (ERM)
family of proteins that mediate cytoskeletal-membrane
interactions and cell signalling [39] to be a target of miR-
183 via perfect complementarity at a binding site at posi-
tion 366-373 of Ezrin 3’UTR. Downregulation of VIL2 as
a result of miR-183 overexpression was validated using
RQ-PCR, indicating that regulation occurred at the
mRNA level, this is in contrast to the findings of Wang
et al [14] who found regulation of Ezrin to be at the post-
transcriptional level in lung cancer. We also found
changes in Ezrin protein expression in breast cancer cells
following transfection with miR-183.
It is likely that much of the migration inhibition
induced by miR-183 in breast cancer cells is modulated
via Ezrin downregulation. Ezrin is a membrane cytoske-
leton crosslinker which plays a role in cell functions
including control of the actin cytoskeleton, adhesion
and motility. The actin cytoskeleton is a highly dynamic
network of actin polymers and proteins and is required
for cell motility, cortical organisation and cell division.
Ezrin has been shown to be a key component in tumor
metastasis [40,41] and is associated with metastatic
potential and poor outcome in breast carcinomas
[42,43].
The assessment of Ezrin expression in breast cancer
cells can be both cytoplasmic and membranous, how-
ever the differential localization, rather than total Ezrin
protein levels is associated with the malignant potential
of the cell. In an immunohistochemical analysis of Ezrin
in primary breast tumors and lymph node metastases,
expression levels of Ezrin protein were significantly
higher in primary cancer tissues than lymph node
metastases but the Ezrin staining pattern was seen
mainly in the membrane region of primary cancer cells,
whereas mainly in cytosols of metastatic cancer cells,
indicating that the subcellular location of Ezrin protein
in breast cancer is integral to the metastatic potential of
the cell [44]. Interestingly, the immunocytochemical
analysis of T47D cells for Ezrin expression following
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http://www.biomedcentral.com/1471-2407/10/502
Page 10 of 12
transfection with miR-183 demonstrated more membra-
nous staining in the transfected cells, which is in keep-
ing with less metastatic potential (figure 6a). These were
the cells that demonstrated decreased migration on
functional analysis. In the SKBR-3 cells which did not
exhibit decreased migration, there appeared to be
decreased membranous and cytoplasmic expression of
Ezrin in the transfected cells (figure 6b), this suggests
that the overexpression of miR-183 in these cells had
disrupted Ezrin expression but this had not translated to
a measurable functional effect.
These results imply that there is an important regula-
tory role of miR-183 in breast cancer, centering on cell
migration and metastatic potential.
Conclusion
The identification of the molecular mechanisms respon-
sible for aggressive tumor behaviour and metastasis is
important for understanding disease progression, guid-
ing disease management, and developing potentially
novel cancer treatment strategies. The elucidation of the
functional role of miR-183 in breast cancer promises to
provide an important avenue for further analysis in in-
vivo systems with an aim to develop a new diagnostic
and therapeutic target in the management of metastatic
breast cancer.
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